Cargando…

Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor

Trastuzumab (Tz), an antibody targeting ERBB2, has significantly improved the prognosis for breast cancer (BCa) patients with overexpression of the ERBB2 receptor. However, Tz resistance poses a challenge to patient outcomes. Numerous mechanisms have been suggested to contribute to Tz resistance, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortese, Katia, Ponassi, Marco, Profumo, Aldo, Coronel Vargas, Gabriela, Iervasi, Erika, Gagliani, Maria Cristina, Bellese, Grazia, Tavella, Sara, Castagnola, Patrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304830/ https://www.ncbi.nlm.nih.gov/pubmed/37367744 http://dx.doi.org/10.3390/membranes13060540

Ejemplares similares

Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2(+) breast cancer cells
por: D’Alesio, Carolina, et al.
Publicado: (2017)

Trastuzumab Modulates the Protein Cargo of Extracellular Vesicles Released by ERBB2(+) Breast Cancer Cells
por: Marconi, Silvia, et al.
Publicado: (2021)

Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
por: Castagnola, Patrizio, et al.
Publicado: (2016)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells
por: Bagnato, Paola, et al.
Publicado: (2017)

Regioselective Synthesis, Structural Characterization, and Antiproliferative Activity of Novel Tetra-Substituted Phenylaminopyrazole Derivatives
por: Lusardi, Matteo, et al.
Publicado: (2022)

Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal Are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines
por: Cortese, Katia, et al.
Publicado: (2020)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Bicyclic Basic Merbarone Analogues as Antiproliferative Agents
por: Spallarossa, Andrea, et al.
Publicado: (2021)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
por: Wang, Lingfei, et al.
Publicado: (2017)

An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
por: Lu, Qiong, et al.
Publicado: (2016)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells
por: Wang, Chao, et al.
Publicado: (2021)

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
por: Lewis Phillips, Gail, et al.
Publicado: (2021)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

A novel calix[4]pyrrole derivative as a potential anticancer agent that forms genotoxic adducts with DNA
por: Geretto, Marta, et al.
Publicado: (2018)

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
por: Durcker, Arik, et al.
Publicado: (2020)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
por: Drucker, Arik, et al.
Publicado: (2020)

Molecular distinctions among ERBB2-overexpressing breast cancers
por: Jeffrey, SS
Publicado: (2005)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
por: Huang, Jingcao, et al.
Publicado: (2013)

Proteomic Analysis of Vessels in Migraine Surgery
por: Raposio, Edoardo, et al.
Publicado: (2023)

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance
por: Sahin, Özgür, et al.
Publicado: (2009)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
por: Bailey, Tameka A., et al.
Publicado: (2011)

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
por: Disel, Umut, et al.
Publicado: (2015)

Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab
por: Tao, Chi-Wei, et al.
Publicado: (2020)

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
por: Tang, Zhiyuan, et al.
Publicado: (2022)

Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab
por: Wei, Yi-Chou, et al.
Publicado: (2023)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy
por: Bychkov, Dmitrii, et al.
Publicado: (2021)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
por: Neil, Alexander J., et al.
Publicado: (2023)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m847q3bg8rsdqbciehk17f8uo5